Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Strand eyes US, Southeast Asia mkts for blood-based cancer screening test

Reliance-backed genomics company is pursuing US FDA approval for CancerSpot and aims to cut its price in India to below ₹10,000 over the next two to three years.

Strand eyes US, Southeast Asia mkts for blood-based cancer screening test

We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.

Read the original at business-standard.com →

More in Health & Medicine

More from Friday 20 November →